Hernia mesh lawsuit update: where the Bard settlement stands, the Covidien bellwether trial starting July 2026, who can still file, and what cases are worth

The hernia mesh litigation is the largest active medical device mass tort in the country, and mid-2026 finds it split into two very different stories. The Bard cases have settled and are grinding through payment administration. The Covidien cases are just reaching their first trial. Understanding which story your case belongs to determines everything: what it's worth, how long it takes, and whether you can still file at all.

How many hernia mesh lawsuits are pending in 2026?

Roughly 26,000 hernia mesh cases are pending across four federal MDLs as of mid-2026. The Bard/Davol litigation (MDL 2846) accounts for approximately 23,600 of them, Covidien (MDL 3029) holds about 2,400, Atrium's C-QUR litigation (MDL 2753) is winding down with around 200, and the Ethicon Physiomesh MDL is largely resolved.

The Bard number requires interpretation. Most of those 23,600 plaintiffs are not litigating; they're waiting. The October 2024 global settlement resolved the bulk of the inventory, and the pending count reflects claims moving through documentation review, lien resolution, and payment processing rather than active courtroom fights. The docket shrinks slowly each month as settled claims are dismissed and new filings partially offset them.

What is the status of the Bard hernia mesh settlement?

Bard's parent company Becton Dickinson announced a global settlement in October 2024 resolving approximately 38,000 claims across the federal MDL and Rhode Island state court, with the total estimated above $1 billion based on the company's litigation reserves. The settlement is now in its payment phase: a court-approved Qualified Settlement Fund has been established, and payments are being processed in order of filing date, earliest cases first.

The framework is a tiered, points-based system. Compensation depends on the number of revision surgeries, the severity of complications (organ perforation, bowel resection, chronic infection), documented chronic pain, hospitalization length, and hernia recurrence. Plaintiffs with a single revision surgery and moderate complications fall into middle tiers; plaintiffs with multiple surgeries, organ damage, or permanent disability occupy the top tiers.

Two realities frustrate settled plaintiffs. First, the gap between "settlement announced" and "check received" is measured in many months, sometimes years, because each claim requires updated medical records, proof of implant, proof of revision, and resolution of Medicare, Medicaid, and private-insurer liens before payment. Second, for claims that don't resolve through the standard framework, the court has scheduled an Intensive Settlement Process beginning January 2027, projected to run through 2029. This litigation will not fully close for years.

The presiding judge is Edmund A. Sargus, Jr. in the Southern District of Ohio, and the products at issue are Bard's polypropylene mesh lines, including Ventralex, PerFix, 3DMax, and Composix Kugel. Individual verdicts before the settlement signaled the stakes: the Trevino case in Rhode Island state court produced a $4.8 million jury verdict (reduced to $4.55 million post-trial), and earlier Kugel-patch litigation settled for $184 million covering roughly 2,600 plaintiffs.

What is happening with the Covidien hernia mesh lawsuit?

The Covidien litigation (MDL 3029, District of Massachusetts, Judge Patti B. Saris) reached its first bellwether trial on July 13, 2026. The case, Patterson v. Covidien, involves Symbotex mesh and allegations of bowel adhesions, obstruction, and major corrective surgery. Judge Saris denied Covidien's summary judgment motion, finding sufficient evidence for a jury to consider claims that the company misrepresented the mesh's ability to prevent internal tissue adhesions.

The Covidien docket holds about 2,400 cases, and plaintiffs' attorneys are notably more bullish on these cases than they were on Bard. The reasoning: the alleged design defects in Covidien's Parietex and Symbotex product lines (particularly the collagen barrier's failure to prevent adhesions) are viewed as stronger liability facts, and the injury profiles in the docket skew more severe. Many plaintiff-side observers expect Covidien settlement values to exceed the Bard framework if the bellwethers produce plaintiff verdicts.

This trial matters beyond the individual case. Bellwether outcomes are the primary driver of mass-tort settlement negotiations: a significant plaintiff verdict in Patterson would pressure Covidien (owned by Medtronic) toward a global resolution, while a defense verdict would slow the litigation and depress settlement expectations. The February 2026 trial date was postponed to July partly to allow settlement discussions; those discussions did not produce a deal, so the case is being tried.

Can you still file a hernia mesh lawsuit in 2026?

Yes, but the practical bar has risen substantially, and it differs by manufacturer.

For Bard cases, new filings continue (December 2025 alone saw over 100 new cases), but the court now requires plaintiffs to name a supporting expert for each case at the time of filing. That's an unusual and demanding requirement that reflects the court's desire to filter weak claims from the post-settlement docket. New filers also face the reality that their claims likely won't resolve until the Intensive Settlement Process runs, potentially past 2029. Most attorneys are now accepting only strong Bard cases: documented revision surgery, clear operative reports connecting the mesh to the complications, and injuries within the statute of limitations.

For Covidien cases, the docket is still growing and the litigation is earlier in its arc. Plaintiffs with Parietex or Symbotex implants and documented complications (adhesions, obstruction, migration, infection, revision surgery) are being actively signed. The bellwether outcomes through 2026 will shape whether this docket grows into a Bard-scale inventory or resolves faster.

The statute of limitations is the hard constraint in both. Most states allow one to three years from the date you knew or should have known the mesh caused your injury (the discovery rule). If your revision surgery happened years ago, the clock has likely been running since then. If complications are emerging now from an implant placed a decade ago, the discovery rule may preserve your claim. This state-by-state variation is why prompt attorney evaluation matters more than any other factor.

What injuries qualify for a hernia mesh claim?

The qualifying complications are consistent across manufacturers: mesh migration (the device moving from the implant site), chronic infection requiring treatment or removal, adhesion formation (the mesh binding to bowel or organs), bowel obstruction or perforation, organ damage, chronic pain persisting six months or longer, hernia recurrence caused by device failure, and revision surgery to repair, reposition, or remove the mesh.

Revision surgery is the value threshold. A claim with documented revision surgery and operative reports describing mesh failure sits in an entirely different tier than a claim alleging pain without surgical intervention. The medical records are the case: the operative report from the original implant (identifying the specific mesh product), imaging showing the complication, and the revision operative report describing what the surgeon found.

The FDA continues to monitor hernia mesh adverse events, tracking reports of pain, infection, recurrence, adhesion, obstruction, and migration. The FDA's device database and prior recalls (including the Kugel patch recalls that launched the first wave of this litigation) remain relevant evidence.

How does the hernia mesh litigation compare to other active mass torts?

Hernia mesh sits alongside several other active pharmaceutical and device litigations covered in this pillar. The Depo-Provera meningioma litigation reached a global settlement in principle in June 2026 after barely 16 months as an MDL, one of the fastest resolutions in mass-tort history. The hair relaxer litigation continues developing in MDL 3060. The Ozempic and GLP-1 gastroparesis litigation is earlier in its arc.

The hernia mesh cases illustrate the full lifecycle: filed in waves starting in the mid-2010s, consolidated, tried through bellwethers, settled at scale in 2024, and now paying claims while a second manufacturer's docket heads to trial. For claimants evaluating any mass tort, the hernia mesh timeline is the realistic template: years from filing to payment, with the settlement tiers ultimately determined by documented injury severity.

What should you do if you have mesh complications?

Request your complete medical records now, before evaluating a claim. The essential documents: the operative report from your original hernia repair (this identifies the mesh manufacturer and product, which determines which litigation your claim belongs to), all imaging since the implant, records of complications and treatment, and any revision surgery operative reports.

Then consult a mass-tort attorney promptly. Consultations are free, representation is contingency-based, and the statute-of-limitations analysis is state-specific and unforgiving. An attorney can identify your mesh product from the operative report, determine which MDL or state court your claim belongs in, and evaluate whether your injury profile meets the current acceptance criteria. The window for new claims is open but narrowing; each year adds limitations problems, and the settlement funds do not stay open indefinitely.